Horizon Pharma Announces Early Termination of Hart-Scott-Rodino Waiting Period for Acquisition of Vidara Therapeutics International Ltd

Horizon Pharma, Inc.

today announced that it has received notice of the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, in connection with its proposed acquisition of Vidara Therapeutics International Ltd. ("Vidara"). The waiting period was scheduled to expire on May 1, 2014. Completion of the transaction remains subject to approval by Horizon's stockholders and other customary closing conditions. Horizon and Vidara previously announced their entry into a definitive agreement under which Horizon will acquire Vidara through a reverse merger for stock and cash. Vidara will be renamed Horizon Pharma plc. Horizon Pharma plc will be organized under the laws of Ireland with a portfolio of four products marketed primarily in the United States. Pursuant to the agreement, Vidara will combine with Horizon with approximately 74 percent of Horizon Pharma plc's ordinary shares to be exchanged for Horizon's common shares. The shareholders of Vidara will retain approximately 26 percent of Horizon Pharma plc on a fully diluted basis and receive $200 million in cash, subject to certain adjustments. About Horizon Pharma Horizon Pharma, Inc. is a commercial stage, specialty pharmaceutical company that markets DUEXIS®, VIMOVO® and RAYOS®/LODOTRA®, which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire or in-license additional innovative medicines where it can execute a targeted commercial approach among specific target physicians such as primary care physicians, orthopedic surgeons and rheumatologists, while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit www.horizonpharma.com.